Last reviewed · How we verify
NCT04259372
Analysis of T Cell Metabolism in Acute Myeloid Leukemia Patients
trial in Acute Myeloid Leukemia in 77 participants. Completed in 31 December 2019.
31 December 2019
Quick facts
| Lead sponsor | University of Freiburg |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 77 |
| Start date | 1 January 2016 |
| Primary completion | 31 December 2019 |
| Estimated completion | 31 December 2019 |
Conditions studied
- Acute Myeloid Leukemia — all drugs for Acute Myeloid Leukemia →
Sponsor
University of Freiburg
Who can join
18 and older, any sex, with Acute Myeloid Leukemia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The objective of this study was to analyze the T cell metabolism and immune phenotype in AML patients during the course of the disease before and after allo-HCT.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Metabolic reprogramming of donor T cells enhances graft-versus-leukemia effects in mice and humans.
Uhl FM, Chen S, O'Sullivan D, Edwards-Hicks J, et al · · 2020 · cited 110× · PMID 33115954 · DOI 10.1126/scitranslmed.abb8969
Verify or expand the search:
- PubMed search for NCT04259372
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Acute Myeloid Leukemia
Currently open trials in the same condition.
- NCT07020533 — A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Pa · Phase 1 · recruiting
- NCT06782542 — Olutasidenib, Venetoclax, and Azacitidine in IDH1 Mutated Newly Diagnosed Acute Myeloid Leukemia Patients Eligible for I · Phase 2 · recruiting
- NCT07177079 — High-dose Ascorbate (HDA) in Combination With Standard of Care Azacitidine and Venetoclax in Acute Myeloid Leukemia (AML · Phase 1 · recruiting
- NCT07384715 — First-in-human (FIH) Trial of GEN3018 in Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-risk Myelod · Phase 1 · recruiting
- NCT07107126 — Safety and Proof-of-Concept Study of RPT1G in Adults With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes · Phase 1 · recruiting
Other University of Freiburg trials
Trials by the same sponsor.
- NCT07517731 — Using Digital Technology for the Prevention of Aedes-Borne Diseases in Colombian Communities · NA · completed
- NCT07053631 — Investigation of a New Window Into Intracranial Pressure: Venous Occlusion Pressure of the Isolated Periorbital Vein · NA · recruiting
- NCT06301412 — Combination of Hypothermia and Thrombectomy in Acute Stroke · Phase 3 · recruiting
- NCT06074874 — Intestinal Biomarker Analysis After ECP for ICI Colitis · completed
- NCT05414552 — ECP for Immune-related Adverse Events After Checkpoint Inhibitor Treatment · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04259372 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Freiburg
- Last refreshed: 6 February 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04259372.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing